2016 top 10 global pharmaceutical companies forecast: how many blocks does Pfizer Elgin leave behind other companies?

Source: pharmaceutical economic news 2016-01-19 the good time of pharmaceutical industry is still continuing, and the production rate of drug research and development is expected to remain at a high level Even though the boom of biological similar drugs in the United States is coming, compared with the expectation, patent expiration is still not worth worrying for many companies Evaluatepharma recently released the 2016 prospective report of the pharmaceutical industry The report points out that the new drug market keeps a rapid pace starting in 2013 This year, it is expected that as many as 12 best-selling drugs will be launched, and these drugs are expected to achieve annual sales of US $1 billion by 2020 At the same time, only six "blockbusters" are facing loss of market franchise this year, and one of them, Humira, is not expected to face direct competition But in this case, the attitude of investors towards the biopharmaceutical industry is still cooling This is mainly because policy makers are constantly questioning drug pricing and tax avoidance, which hinders the enthusiasm of investors Continuing to review pricing could be a factor in weakening investor confidence and leading to further cooling of the pharmaceutical industry The gradual decline in market valuations is not enough to make acquirers eat up large pharmaceutical companies, although many will eventually need to buy to re fill their product lines In 2015, only Pfizer took action to complete a large acquisition In 2016, large pharmaceutical companies will continue to be active in small-scale mergers and acquisitions, but unless valuations continue to decline, their acquisition strategies will focus on key businesses, and continue to grow to prevent themselves from being acquired, especially relatively small companies However, companies like AstraZeneca, Sanofi and Gilead, which need to speed up the improvement of their product lines, are likely to make large-scale acquisitions against the trend in 2016 No.1 in pharmaceutical industry: hit $70.4 billion in annual sales Through the prediction of drug sales of major pharmaceutical companies in 2016, evaluatepharma listed the top ten pharmaceutical companies in the world Novartis and Pfizer have been competing for the top spot in sales since Pfizer's Lipitor lost patent protection in 2011, and the competition will continue in 2016, when M & A activity is absent However, if Pfizer's acquisition of Elgin can be completed in 2016, it will be on the top of the list In 2016, Pfizer Elgin's portfolio will win the title of the world's largest pharmaceutical company with $70.4 billion in sales of prescription and over-the-counter drugs, leaving Novartis and other large pharmaceutical companies far behind In the absence of any other major acquisitions, Novartis will remain No 2, thanks to the launch of its heart disease drug entresto and the continuous sales revenue from patent drugs such as gilenya, Tasigna and afinitor The Swiss pharmaceutical group is being hampered by a lack of innovation, particularly with Alcon's eye business now on a plateau Roche will remain in third place; Sanofi, who has suffered setbacks in the field of diabetes, will be in fourth place With the launch of praluent and dupilumab, as well as the growth of aubagio and lemtrada, Sanofi will perform prominently in 2016; Merck & Co's 5th place will also be safe; but the equally powerful GlaxoSmithKline and Johnson &Johnson) will compete for the 6th place More bad news from GSK's respiratory medicine market franchise, or more good news from inbruvica, a joint venture between Johnson and Aberdeen, may change this situation Gilead has done well, moving from a mid sized biotech company to a large pharmaceutical company This is mainly due to the patent of hepatitis C drugs, but the market is mature Geely may want to diversify through acquisitions, which may boost its ranking The last two companies on the list are abbvie and AstraZeneca, which have different performances AstraZeneca's ranking has declined due to the expiration of drug patents, while EBV's sales are increasing due to the acquisition of pharmacyclics and its anticancer drug imbruvica Best selling drugs: Sumeria's position is hard to regret Although with the emergence of Pfizer Elgin, the largest pharmaceutical company will change in 2016, the change of the best-selling drugs is very small Although drugs such as tenofovir and atezolizumab will leap to the top in the next few years, and biological preparations will meet new competitors in 2016 with the step-by-step pressure of biological similar drugs, the latter will have a long way to go before the current best-selling drugs can be driven down the throne In 2016, the glory of the best-selling drugs will once again be attributed to Sumeria The annual sales revenue is expected to be 15.7 billion US dollars, 4.1 billion US dollars more than the second place in the top 10 list of the best-selling drugs, almost the total historical sales of GlaxoSmithKline's advair But Amgen has submitted abp501, a similar product, to the FDA for approval, and the absolute size of Sumeria's sales suggests that Aberdeen is at a critical juncture Most companies will be satisfied with just one product on the list, while Roche has three seats in the list, and the antineoplastic drugs rituxan, Avastin and Herceptin are expected to generate a total of $20 billion in sales revenue in 2016 Although Roche does not rely on a single product like Aberdeen, the company's previously impeccable drugs are now in danger of competing for bioequivalent drugs REMICADE is low on the list, in part because the drug has already faced competition from similar biologicals in Europe Lantus is still on the list, but it is also in a tough situation, with sales expected to fall from $7.4 billion to $6.9 billion This was mainly affected by the market entry of Lilly's biological analogue, basaglar, and the introduction of Novo Nordisk's long-acting insulin tresiba One of the top 10 best selling drugs, Seretide, is facing strong pricing pressure, with sales expected to halve by 2020 This is mainly due to the increasing voice of drug welfare management institutions If there is competition in a drug category, it has an opportunity to consider replacing one drug with another in exchange for a reduction in price In 2015, GlaxoSmithKline was forced to slash the price of its flagship drug to bring it back to prescription concentration It also raises concerns that this is a potential signal to other players in the industry that their pricing power could collapse For harvoni, although the outlook for 2016 looks good, its sales will also fall from the $14 billion expected in 2015 The change of hepatitis C drug market means that many patients in stock have completed treatment at present At the same time, competition from a range of new drugs will weaken the dominance of the drug Under the competitive pressure mentioned above, there are still some top-10 drugs that can see sales growth Relvimid has ensured a strong position in the first-line treatment of multiple myeloma, and prevnar 13 has also been in a leading position in the field of pneumococcal vaccine The two drugs are expected to climb in the next few years.